AKEBIA THERAPEUTICS, INC. Line of Credit Facility, Maximum Borrowing Capacity
AKEBIA THERAPEUTICS, INC. (AKBA) had Line of Credit Facility, Maximum Borrowing Capacity of $40.00 million as of 2019-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2021-02-25
- 2019-12-31: Line of Credit Facility, Maximum Borrowing Capacity $40.00M.
- 2019-09-30: Line of Credit Facility, Maximum Borrowing Capacity $40.00M.
- 2019-06-30: Line of Credit Facility, Maximum Borrowing Capacity $40.00M.
- 2019-03-31: Line of Credit Facility, Maximum Borrowing Capacity $40.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2019-12-31 | $40.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $40.00M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $40.00M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $40.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $40.00M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |